Update on investigational formulation of inhaled rapamycin (mTOR inhibitor) for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome after lung transplant, October 9, 2026

Quince Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, has announced that it has changed its name to IRulya Therapeutics Inc. IRulya will be focused on advancing LAM-001, an investigational formulation of inhaled rapamycin (mTOR inhibitor) for multiple pulmonary diseases. LAM-001 is a […]

Update on investigational formulation of inhaled rapamycin (mTOR inhibitor) for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome after lung transplant, October 9, 2026 Read Post »

Pulmonary arterial hypertension (PAH) in the era of obesity: navigating phenotypes of pulmonary hypertension, Expert Review of Respiratory Medicine, October 22, 2026

An article published recently on the Expert Review of Medicine reviews the epidemiology of obesity and its impact on pulmonary arterial hypertension. The typical patient has changed over the years from a young, lean, woman to an older person with other conditions such as obesity, diabetes or heart disease. Obesity is now one of the

Pulmonary arterial hypertension (PAH) in the era of obesity: navigating phenotypes of pulmonary hypertension, Expert Review of Respiratory Medicine, October 22, 2026 Read Post »

First Report of Real World Utilization of an Activin Signaling Inhibitor in Patients With Severe Pulmonary Arterial Hypertension in the Middle East, Pulmonary Circulation, October 22, 2026

Researchers from a tertiary pulmonary hypertension expert center in Abu Dhabi, United Arab Emirates, conducted a retrospective single-center cohort study (PH RISE-ME) evaluating the real-world effectiveness and safety of sotatercept in adults with pulmonary arterial hypertension already on optimised background therapy. The findings reveal that adding sotatercept In this cohort was associated with improved right-heart

First Report of Real World Utilization of an Activin Signaling Inhibitor in Patients With Severe Pulmonary Arterial Hypertension in the Middle East, Pulmonary Circulation, October 22, 2026 Read Post »

Platelet–Albumin–Bilirubin Index (PALBI) for Predicting Hospitalization and Mortality in Pulmonary Hypertension, Circulation Journal, October 23, 2026

A retrospective study by researchers in Turkey looked at a simple index based on three routine blood measurements: platelets, albumin and bilirubin. The “PALBI” index reflects how pulmonary hypertension affects both the heart and the liver. Researchers applied it to 3,432 people, including 1,520 patients with pulmonary hypertension identified by echocardiography. The final cohort comprised

Platelet–Albumin–Bilirubin Index (PALBI) for Predicting Hospitalization and Mortality in Pulmonary Hypertension, Circulation Journal, October 23, 2026 Read Post »

Impaired BMPR2 signalling across pulmonary hypertension subgroups: a multicentre study, European Respiratory Journal Open Research, September 28, 2026

A multicentre German study, run at specialist centres in Heidelberg, Hannover and Giessen/Marburg, looked at the key gene in pulmonary hypertension, BMPR2. Changes in this gene cause most inherited cases of pulmonary arterial hypertension, and the biological pathway it controls is also the target of sotatercept. The researchers took blood samples from 234 people in

Impaired BMPR2 signalling across pulmonary hypertension subgroups: a multicentre study, European Respiratory Journal Open Research, September 28, 2026 Read Post »

Researchers at Brown University, USA, find that molecular profiles may help create more effective individualized treatment for pulmonary arterial hypertension, The Brown Daily Herald, October 15, 2026

In a retrospective study, researchers at Brown University looked back at data from patients with pulmonary arterial hypertension. Their cells had been collected from the lung blood vessels during routine catheter procedures. After they collected the cells, the researchers sequenced the cells’ RNA content. Next, they used a bioinformatics pipeline to determine which specific molecular

Researchers at Brown University, USA, find that molecular profiles may help create more effective individualized treatment for pulmonary arterial hypertension, The Brown Daily Herald, October 15, 2026 Read Post »

Update on the global Phase IIb EPIMODE trial evaluating drug candidate CS1 in pulmonary arterial hypertension (PAH), Modular Finance, October 8, 2026

EPIMODE is a global, randomized and placebo-controlled Phase IIb trial designed to evaluate efficacy, safety and tolerability, determine the optimal dose for further development, and provide additional insight into CS1’s potential disease-modifying effects in patients with pulmonary arterial hypertension (PAH). CS1 is being developed by Cereno Scientific as an oral, once-daily, potentially disease-modifying treatment for

Update on the global Phase IIb EPIMODE trial evaluating drug candidate CS1 in pulmonary arterial hypertension (PAH), Modular Finance, October 8, 2026 Read Post »

What’s new on the Pulmonary Hypertension Knowledge Sharing Platform – September 2026

September was a busy month in the pulmonary hypertension world, with the European Society of Cardiology (ESC) and European Respiratory Society Congresses (ERS) bringing a wave of new research. The most important news is the update of the ERS Clinical Practice Guidelines for the treatment of pulmonary arterial hypertension (PAH), presented in Barcelona. AfPH Vice

What’s new on the Pulmonary Hypertension Knowledge Sharing Platform – September 2026 Read Post »

Reduced brain blood flow, heart strain, and cognitive symptoms in pulmonary arterial hypertension, Therapeutic Advances in Respiratory Diseases, Jan-Dec 2026

Some patients with pulmonary arterial hypertension experience difficulties with memory, thinking, or mood. A group of Chinese researchers have investigated whether reduced blood flow to the brain is connected to heart strain and disease severity. They compared brain scans from 30 people with pulmonary arterial hypertension and 51 healthy individuals matched for age and sex.

Reduced brain blood flow, heart strain, and cognitive symptoms in pulmonary arterial hypertension, Therapeutic Advances in Respiratory Diseases, Jan-Dec 2026 Read Post »

Pulmonary hypertension associated with interstitial lung disease: a state-of-the-art review, European Respiratory Journal, Vol 68 Issue 1

Following the 7th World Symposium on Pulmonary Hypertension, a review published in the European Respiratory Journal summarises the current understanding of Pulmonary hypertension associated with interstitial lung disease (PH-ILD). It covers the condition’s clinical features, underlying biology, diagnosis, prognosis and treatment, while flagging diagnostic challenges — from overlapping symptoms to the lack of specific biomarkers

Pulmonary hypertension associated with interstitial lung disease: a state-of-the-art review, European Respiratory Journal, Vol 68 Issue 1 Read Post »

The Pulmonary Vascular Research Institute (PVRI) publishes a 13-part series to help people living with pulmonary hypertension (PH), their families, and carers understand clinical trials,

This series was created by the IDDI Patient Engagement and Empowerment Workstream, of the Pulmonary Vascular Research Institute (PVRI), whose members are Hall Skaara, Louise Bouman, Jamie Myrah, Colleen Brunetti, Luke Howard, Gil Golden, Vera Toth-Fejel, Wendy Gin-Sing. The series explains what clinical trials are, how they work, and what it means to take part. All

The Pulmonary Vascular Research Institute (PVRI) publishes a 13-part series to help people living with pulmonary hypertension (PH), their families, and carers understand clinical trials, Read Post »

Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the FONCE-HTAP randomized controlled trial, Annals of the American Thoracic Society, July 20, 2026

The findings of a multi-center randomized controlled trial investigating the long-term efficiency of rehabilitation in patients with pulmonary arterial hypertension was published in the Annals of the American Thoracic Society on July 20, 2026. The study followed 47 patients with stable pulmonary arterial hypertension across 9 French centers, looking at the long-term impact of a

Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the FONCE-HTAP randomized controlled trial, Annals of the American Thoracic Society, July 20, 2026 Read Post »

Predictive Power of Pulmonary Artery Stiffness – Right Ventricular Interplay, but not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension: A PVRI GoDeep meta-registry analysis, CHEST, August 26, 2026

In a recent LinkedIn post Prof. Werner Seeger writes that the GoDeep meta-registry analysis about the predictive power of pulmonary artery stiffness – right ventricular interplay in mild pulmonary hypertension (PH) is now online. He reports that in the analysis, notably, parameters integrating pulsatile vascular load and interdependent right ventricular function possess predictive power independent

Predictive Power of Pulmonary Artery Stiffness – Right Ventricular Interplay, but not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension: A PVRI GoDeep meta-registry analysis, CHEST, August 26, 2026 Read Post »

Multicentre study explores impaired bone morphogenetic protein receptor 2 (BMPR2) signalling across pulmonary hypertension subgroups, European Respiratory Journal Open Research 2026

A multicentre study recently published on the European Respiratory Journal Open Research looked at bone morphogenetic protein receptor 2 (BMPR2) signalling — a pathway already known to be disrupted in heritable pulmonary arterial hypertension (PAH) — across a wider range of pulmonary hypertension (PH) patients, to see whether the same disturbance shows up in other

Multicentre study explores impaired bone morphogenetic protein receptor 2 (BMPR2) signalling across pulmonary hypertension subgroups, European Respiratory Journal Open Research 2026 Read Post »

Study finds that early parenteral prostacyclin therapy enables near-normal haemodynamics in severe pulmonary arterial hypertension patients, European Respiratory Journal, July 16, 2026

In a single-centre Japanese cohort of 101 patients with haemodynamically severe pulmonary arterial hypertension treated with parenteral prostacyclin (1999–2023), 22 patients (22%) achieved near-normal haemodynamics and were successfully weaned off prostacyclin, all without adverse events, after a mean of 7.7 years of treatment. Those who de-escalated tended to have started prostacyclin earlier in their disease

Study finds that early parenteral prostacyclin therapy enables near-normal haemodynamics in severe pulmonary arterial hypertension patients, European Respiratory Journal, July 16, 2026 Read Post »

Placental growth factor promotes endothelial activation and inflammatory remodelling in pulmonary hypertension, Cardiovascular Research, July 1, 2026

Could a new protein become a future treatment target in pulmonary arterial hypertension(PAH)? Researchers have identified a protein called placental growth factor (PlGF) as a possible new driver of pulmonary arterial hypertension (PAH). Although its name suggests it is only involved in pregnancy, placental growth factor is also active in blood vessels and the immune

Placental growth factor promotes endothelial activation and inflammatory remodelling in pulmonary hypertension, Cardiovascular Research, July 1, 2026 Read Post »

Study finds combining mindfulness with rehab exercise improves cardiopulmonary performance and psychological stress in pulmonary arterial hypertension patients, Canadian Respiratory Journal, June 29, 2026

Researchers at the Suqian First Hospital in Suqian, Chian, China tested whether adding mindfulness-based stress reduction (MBSR) to standard cardiopulmonary rehabilitation could benefit pulmonary arterial hypertension patients more than usual care alone. Fifty stable patients were split into two groups: one did a 6-week combined mindfulness-based stress reduction and rehab program, the other received standard

Study finds combining mindfulness with rehab exercise improves cardiopulmonary performance and psychological stress in pulmonary arterial hypertension patients, Canadian Respiratory Journal, June 29, 2026 Read Post »

Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension, Frontiers in Cardiovascular Medicine, May 21, 2026

This single-center retrospective study, conducted at Qilu Hospital, Shandong University (China), from February 2022 to November 2023, set out to compare two strategies for selexipag-based triple combination therapy in patients with pulmonary arterial hypertension (PAH): starting all three drugs together (initial/upfront triple therapy) versus adding selexipag on top of existing dual therapy (early sequential triple

Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension, Frontiers in Cardiovascular Medicine, May 21, 2026 Read Post »

Haemodynamic Responses to Sotatercept and Parenteral Prostacyclins in Pulmonary Arterial Hypertension Patients, Journal of Heart and Lung Transplantation, June 1, 2026

French researchers retrospectively evaluated the haemodynamic trajectory of 62 patients with pulmonary arterial hypertension (PAH) who sequentially received parenteral prostacyclins and sotatercept as part of the French early access program. They found that both treatments lowered the resistance in the blood vessels of the lungs, making it easier for blood to flow. However, the treatments worked

Haemodynamic Responses to Sotatercept and Parenteral Prostacyclins in Pulmonary Arterial Hypertension Patients, Journal of Heart and Lung Transplantation, June 1, 2026 Read Post »

TRANSLATE »
Scroll to Top